Detalhe da pesquisa
1.
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma.
Haematologica
; 108(11): 2894-2912, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37608773
2.
Using Proteomics Data to Identify Personalized Treatments in Multiple Myeloma: A Machine Learning Approach.
Int J Mol Sci
; 24(21)2023 Oct 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37958554
3.
Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma.
Am J Hematol
; 97(5): 562-573, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35132679
4.
Clinical Proteomics of Biofluids in Haematological Malignancies.
Int J Mol Sci
; 22(15)2021 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34360786
5.
Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types.
Haematologica
; 105(6): 1527-1538, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31439679
6.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 20(6): 781-794, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31097405
7.
Polyclonal Immunoglobulin G N-Glycosylation in the Pathogenesis of Plasma Cell Disorders.
J Proteome Res
; 16(2): 748-762, 2017 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27936757
8.
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
Eur J Haematol
; 99(3): 199-206, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28504846
9.
Successful treatment of solitary bone plasmacytoma and bone remineralisation with novel biological agents leading to new bone formation - a case series.
Br J Haematol
; 193(4): e36-e38, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33748981
10.
Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma.
Br J Haematol
; 173(1): 82-8, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26787413
11.
COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies.
Br J Haematol
; 193(1): 43-51, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33538335
12.
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM).
Am J Hematol
; 91(8): 806-11, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27169523
13.
Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease.
BMC Genomics
; 15: 904, 2014 Oct 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-25322877
14.
Multiple Myeloma Derived Extracellular Vesicle Uptake by Monocyte Cells Stimulates IL-6 and MMP-9 Secretion and Promotes Cancer Cell Migration and Proliferation.
Cancers (Basel)
; 16(5)2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38473370
15.
A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia.
Br J Haematol
; 163(1): 118-22, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23909468
16.
Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures.
Cancers (Basel)
; 15(15)2023 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37568580
17.
A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients.
Proteomics
; 11(8): 1391-402, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21365752
18.
Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers.
Cancers (Basel)
; 13(8)2021 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33923680
19.
Saliva-omics in plasma cell disorders- Proof of concept and potential as a non-invasive tool for monitoring disease burden.
J Proteomics
; 231: 104015, 2021 01 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33068749
20.
Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients.
Sci Rep
; 11(1): 12866, 2021 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34145309